Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy.

Autor: Chand D; Agenus (United States), Lexington, MA, United States., Savitsky DA; Agenus, Lexington, MA, United States., Krishnan S; Agenus (United States), Lexington, MA, United States., Mednick G; Agenus (United States), Lexington, MA, United States., Delepine C; Agenus (United States), Lexington, MA, United States., Garcia-Broncano P; Agenus (United States), Lexington, MA, United States., Soh KT; Agenus (United States), Lexington, MA, United States., Wu W; Agenus (United States), Lexington, MA, United States., Wilkens MK; Agenus (United States), Lexington, MA, United States., Udartseva O; Agenus (United States), Lexington, MA, United States., Vincent S; Agenus (United States), Lexington, MA, United States., Joshi B; Agenus (United States), Lexington, MA, United States., Keith JG; Agenus (United States), Lexington, MA, United States., Manrique M; Agenus (United States), Lexington, MA, United States., Marques M; Agenus (United States), Lexington, MA, United States., Tanne A; Agenus (United States), Lexington, MA, United States., Levey DL; Agenus (United States), Lexington, MA, United States., Han H; Translational Genomics Research Institute, Phoenix, AZ, United States., Ng S; TGEN, Phoenix, Arizona, United States., Ridpath J; Agenus (United States), Lexington, MA, United States., Huber O; Agenus (United States), Lexington, MA, United States., Morin B; Agenus Inc., Lexington, MA, United States., Galand C; Agenus (United States), Lexington, MA, United States., Bourdelais S; Agenus (United States), Lexington, MA, United States., Gombos RB; Agenus Inc., Lexington, MA, United States., Ward R; Agenus Inc, Lexington, MA, United States., Qin Y; Agenus (United States), Lexington, MA, United States., Waight JD; GlaxoSmithKline (United States), Collegeville, PA, United States., Costa MR; Agenus (United States), Lexington, MA, United States., Sebastian-Yague A; Agenus (United States), Cambridge, United Kingdom., Rudqvist NP; Agenus (United States), Lexington, MA, United States., Pupecka-Swider M; Agenus (United States), Cambridge, United Kingdom., Venkatraman V; Agenus (United States), Cambridge, United Kingdom., Slee A; Agenus (United States), Lexington, MA, United States., Patel JM; Agenus (United States), Lexington, MA, United States., Grossman JE; Agenus Inc., Lexington, MA, United States., Wilson NS; Agenus Inc., Lexington, MA, United States., Von Hoff DD; Translational Genomics Research Institute, Phoenix, United States., Stebbing J; Anglia Ruskin University, Cambridge, United Kingdom., Curiel TJ; Dartmouth Health and The Geisel Medical School at Dartmouth, Lebanon, NO, United States., Buell JS; Agenus Inc., Lexington, MA, United States., O'Day SJ; Agenus Inc., Lexington, MA, United States., Stein RB; Agenus (United States), Lexington, MA, United States.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31.

Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons.

Autor: Wald A; Department of Medicine, University of Washington, Seattle, WA, USA. annawald@u.washington.edu, Koelle DM, Fife K, Warren T, Leclair K, Chicz RM, Monks S, Levey DL, Musselli C, Srivastava PK

Publikováno v: Vaccine [Vaccine] 2011 Nov 03; Vol. 29 (47), pp. 8520-9. Date of Electronic Publication: 2011 Sep 21.

High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses.

Autor: Flechtner JB; Antigenics Inc., 3 Forbes Road, Lexington, MA 02421, USA., Cohane KP, Mehta S, Slusarewicz P, Leonard AK, Barber BH, Levey DL, Andjelic S

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2006 Jul 15; Vol. 177 (2), pp. 1017-27.